Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)
Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive
Herbal medicinal product: Oenotherae oleumArray, C: ongoing call for scientific data
Herbal medicinal product: MyrrhaArray, C: ongoing call for scientific data
Herbal medicinal product: Melissae foliumArray, C: ongoing call for scientific data
Herbal medicinal product: Curcumae longae rhizomaArray, C: ongoing call for scientific data
Human medicines European public assessment report (EPAR): Metalyse, tenecteplase, Date of authorisation: 23/02/2001, Revision: 23, Status: Authorised
List of signals discussed at PRAC since September 2012
Quarterly System Demo Q1 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2024, 09:00 (CET) to 26 March 2024, 13:30 (CET)
Regulatory information – adjusted fees for applications to EMA from 1 April 2024